Webster Equity Partners and Gurnet Point Capital Acquire Corium's Manufacturing Business and Invest in Corium Neuroscience

HealthQuest Capital and Great Point Partners Invest Growth Equity in Cellipont Bioservices; Darren Head Named CEO

October 7, 2024

Biotechnology

Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.

Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals

September 21, 2023

Pharmaceuticals

Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.

Great Point Partners Completes Growth Recapitalization of Velentium

September 29, 2021

Medical Devices

Great Point Partners completed a growth recapitalization of Houston-based Velentium, a professional engineering and contract medical device manufacturer. The investment will fund Velentium's expansion initiatives — including tuck-in acquisitions and enhanced engineering and manufacturing capabilities — while preserving the company's quality and culture.

Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare

May 25, 2021

Healthcare Services

Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.

Caprion Biosciences Acquires Serametrix Corporation

May 8, 2019

Healthcare Services

Caprion Biosciences, a GHO Capital portfolio company, has acquired Serametrix Corporation, a CLIA-certified immune monitoring services provider headquartered in Carlsbad, California. The deal expands Caprion's immunology biomarker capabilities—notably Serametrix's MDSC analysis expertise—and extends Caprion's global footprint with Serametrix's operations in the US, UK, Australia and China.

Bain Capital Invests up to $300M in Cardurion Pharmaceuticals

October 27, 2021

Biotechnology

Cardurion Pharmaceuticals, a clinical‑stage biotechnology company focused on cardiovascular therapeutics, received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity to advance its PDE9 and CaMKII inhibitor programs and to scale the business. The funding will support a major Phase 2 heart‑failure trial, initiation of first‑in‑human studies, and company growth; Bain Capital will also join Cardurion’s board alongside existing investors Takeda Pharmaceuticals and Polaris Partners.